Inhibition of GSK-3β enhances reovirus-induced apoptosis in colon cancer cells

International Journal of Oncology

Volumn 35, Issue 3, 2009, Pages 617-624

  Min, Hye Jin ^a   Koh, Sang Seok ^b   Cho, Il Rae ^a   Srisuttee, Ratakorn ^a   Park, Eun Hee ^a   Jhun, Byung Hak ^a   Kim, Yong Gyun ^a   Oh, Sangtaek ^c   Kwak, Ju Eun ^d   Johnston, Randal N ^e   Chung, Young Hwa ^a  

^a Pusan National University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Inje University   (South Korea)

^d Pohang University of Science and Technology (POSTECH)   (South Korea)

^e UNIVERSITY OF CALGARY   (Canada)

Author keywords

Catenin; Colon cancer; Glycogen synthase kinase 3 ; Nuclear factor B; Reovirus

Indexed keywords

AR A 014418; BETA CATENIN; CASPASE 8; FRIZZLED 1 PROTEIN; FRIZZLED PROTEIN; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LITHIUM CHLORIDE; ONCOLYTIC REOVIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG; WNT3A PROTEIN; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL STRAIN HEK293; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; UPREGULATION; VIRUS REPLICATION; COLON TUMOR; DRUG ANTAGONISM; DRUG EFFECT; MAMMALIAN ORTHOREOVIRUS; METABOLISM; METHODOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VIROLOGY; VIRUS INFECTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA CATENIN; BLOTTING, WESTERN; CELL LINE, TUMOR; COLONIC NEOPLASMS; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; NF-KAPPA B; ONCOLYTIC VIROTHERAPY; ORTHOREOVIRUS, MAMMALIAN; REOVIRIDAE INFECTIONS; SIGNAL TRANSDUCTION;

EID: 70349149071     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000373     Document Type: Article

References (37)

1. Norman KL, Hirasawa K, Yang AD, Shields MA and Lee PW: Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci USA 101: 11099-11104, 2004.
2. Rosen L, Evans HE and Spickard A: Reovirus infections in human volunteers. Am J Hyg 77: 29-37, 1963.
3. Kim M, Chung YH and Johnston RN: Reovirus and tumor oncolysis. J Microbiol 45: 187-192, 2007.
4. Duncan MR, Stanish SM and Cox DC: Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol 28: 444-449, 1978.
5. Hashiro G, Loh PC and Yau JT: The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol 54: 307-315, 1977.
6. Coffey MC, Strong JE, Forsyth PA and Lee PW: Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332-1334, 1998.
7. Strong JE, Coffey MC, Tang D, Sabinin P and Lee PW: The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 17: 3351-3362, 1998.
8. Hirasawa K, Nishikawa SG, Norman KL, Coffey MC, Thompson BG, Yoon CS, Waisman DM and Lee PW: Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 63: 348-353, 2003.
9. Park EH, Koh SS, Srisuttee R, Cho IR, Min HJ, Jhun BH, Lee YS, Jang KL, Kim CH, Johnston RN and Chung YH: Expression of HBX, an oncoprotein of hepatitis B virus, blocks reoviral oncolysis of hepatocellular carcinoma cells. Cancer Gene Ther (In press).
10. Yang WQ, Lun X, Palmer CA, Wilcox ME, Muzik H, Shi ZQ, Dyck R, Coffey M, Thompson B, Hamilton M, Nishikawa SG, Brasher PM, Fonseca K, George D, Rewcastle NB, Johnston RN, Stewart D, Lee PW, Senger DL and Forsyth PA: Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates. Clin Cancer Res 10: 8561-8576, 2004.
11. Norman KL and Lee PW: Not all viruses are bad guys: the case for reovirus in cancer therapy. Drug Discov Today 10: 847-855, 2005.
12. Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossakowska A and Lee PW: Oncolytic reovirus against ovarian and colon cancer. Cancer Res 62: 1696-1701, 2002.
13. Ikeda Y, Nishimura G, Yanoma S, Kubota A, Furukawa M and Tsukuda M: Reovirus oncolysis in human head and neck squamous carcinoma cells. Auris Nasus Larynx 31: 407-412, 2004.
14. Alain T, Wong JF, Endersby R, Urbanski SJ, Lee PW, Muruve DA, Johnston RN, Forsyth PA and Beck PL: Reovirus decreases azoxymethane-induced aberrant crypt foci and colon cancer in a rodent model. Cancer Gene Ther 14: 867-872, 2007.
15. Clarke P, Meintzer SM, Gibson S, Widmann C, Garrington TP, Johnson GL and Tyler KL: Reovirus-induced apoptosis is mediated by TRAIL. J Virol 74: 8135-8139, 2000.
16. Clarke P, Meintzer SM, Widmann C, Johnson GL and Tyler KL: Reovirus infection activates JNK and the JNK-dependent transcription factor c-Jun. J Virol 75: 11275-11283, 2001.
17. Clarke P, Meintzer SM, Spalding AC, Johnson GL and Tyler KL: Caspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infection. Oncogene 20: 6910-6919, 2001.
18. Frame S and Cohen P: GSK3 takes centre stage more than 20 years after its discovery. Biochem J 359: 1-16, 2001.
19. Woodgett JR: Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 9: 2431-2438, 1990.
20. Doble BW and Woodgett JR: GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116: 1175-1186, 2003.
21. Aberle H, Bauer A, Stappert J, Kispert A and Kemler R: Betacatenin is a target for the ubiquitin-proteasome pathway. EMBO J 16: 3797-3804, 1997.
22. Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, Billadeau DD, Mai M, Takahashi Y and Minamoto T: Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun 334: 1365-1373, 2005.
23. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O and Woodgett JR: Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406: 86-90, 2000.
24. Alain T, Hirasawa K, Pon KJ, Nishikawa SG, Urbanski SJ, Auer Y, Luider J, Martin A, Johnston RN, Janowska-Wieczorek A, Lee PW and Kossakowska AE: Reovirus therapy of lymphoid malignancies. Blood 100: 4146-4153, 2002.
25. Kim M, Egan C, Alain T, Urbanski SJ, Lee PW, Forsyth PA and Johnston RN: Acquired resistance to reoviral oncolysis in Rastransformed fibrosarcoma cells. Oncogene 26: 4124-4134, 2007.
26. Dignam JD, Lebovitz RM and Roeder RG: Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11: 1475-1489, 1983.
27. Ardeshna KM, Pizzey AR, Devereux S and Khwaja A: The PI3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells. Blood 96: 1039-1046, 2000.
28. Klein PS and Melton DA: A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 93: 8455-8459, 1996.
29. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA and Billadeau DD: Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 65: 2076-2081, 2005.
30. Sung J: Colorectal cancer screening: its time for action in Asia. Cancer Detect Prev 31: 1-2, 2007.
31. Takayama T, Ohi M, Hayashi T, Miyanishi K, Nobuoka A, Nakajima T, Satoh T, Takimoto R, Kato J, Sakamaki S and Niitsu Y: Analysis of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis. Gastroenterology 121: 599-611, 2001.
32. Cohen P and Frame S: The renaissance of GSK3. Nat Rev Mol Cell Biol 2: 769-776, 2001.
33. Nelson WJ and Nusse R: Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303: 1483-1487, 2004.
34. Cohen P and Goedert M: GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 3: 479-487, 2004.
35. Shakoori A, Mai W, Miyashita K, Yasumoto K, Takahashi Y, Ooi A, Kawakami K and Minamoto T: Inhibition of GSK-3 beta activity attenuates proliferation of human colon cancer cells in rodents. Cancer Sci 98: 1388-1393, 2007.
36. Kim JW, Lee JE, Kim MJ, Cho EG, Cho SG and Choi EJ: Glycogen synthase kinase 3 beta is a natural activator of mitogen-activated protein kinase/ extracellular signal-regulated kinase kinase kinase 1 (MEKK1). J Biol Chem 278: 13995-14001, 2003.
37. Takada Y, Fang X, Jamaluddin MS, Boyd DD and Aggarwal BB: Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J Biol Chem 279: 39541-39554, 2004.